# US 2017/0281797 A1 · Lactoferrin-conjugated nanoparticle complex and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281797 A1
- Document ID: US20170281797A1
- Status: Published application
- Kind: A1
- Application number: 15/471,905
- Filed: 2017-03-28
- Published: 2017-10-05
- Earliest claimed: 2016-03-29
- Assignees: Industry-University Cooperation Foundation Hanyang University
- Applicants: Industry-University Cooperation Foundation Hanyang University
- Inventors: Dong Yun LEE; Seung Jae LEE; Hyung Shik KIM
- Web page: https://patentgrep.com/patent/US20170281797A1

## CPC

- A61B 18/082: {Probes or electrodes therefor}
- A61K 38/063: {Glutathione}
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention relates to a lactoferrin-conjugated nanoparticle complex and a novel use thereof. In the nanoparticle complex according to the present invention, lactoferrin or polyethylene glycol-lactoferrin is bound to metal nanoparticles, and according to this construction, it can be confirmed that the metal nanoparticles are not only efficiently targeted to the brain tumor tissues, but also the stability of the metal nanoparticles can be maintained even in the in vivo conditions, and thus it is expected in the treatment of brain tumors to be treatable to targets by approaching more fundamentally.

## Claims

### Claim 1

A nanoparticle complex comprising metal nanoparticles, glutathione and lactoferrin.

### Claim 2 (depends on 1)

The nanoparticle complex according to claim 1, wherein said metal nanoparticles are selected from the group consisting of gold nanoparticles, iron oxide nanoparticles, and silver nanoparticles.

### Claim 3 (depends on 1)

The nanoparticle complex according to claim 1, wherein said nanoparticle complex comprises metal nanoparticles surface-modified with lactoferrin and glutathione, and said lactoferrin is surface-modified with a biocompatible polymer.

### Claim 4 (depends on 3)

The nanoparticle complex according to claim 3, wherein said biocompatible polymer is selected from the group consisting of polyethylene glycol, polycaprolactone, polylactic acid, polyglycolic acid, polylactate-co-glycolic acid, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(L-lactide-co-caprolactone), and poly(L-lactide-co-D-lactide).

### Claim 5 (depends on 3)

The nanoparticle complex according to claim 3, wherein said biocompatible polymer has a thiol (—SH) group at one terminal thereof.

### Claim 6 (depends on 3)

The nanoparticle complex according to claim 3, wherein said lactoferrin and glutathione are bound to the metal nanoparticles by disulfide bonds.

### Claim 7 (depends on 1)

The nanoparticle complex according to claim 1, wherein said nanoparticle complex has an average diameter of 4 to 20 nm.

### Claim 8 (depends on 1)

A method of treating brain tumors comprising a step of administering the nanoparticle complex of claim 1 to a subject.

### Claim 9 (depends on 8)

The method of treating brain tumors according to claim 8, wherein said metal nanoparticles are selected from the group consisting of gold nanoparticles, iron oxide nanoparticles, and silver nanoparticles.

### Claim 10 (depends on 8)

The method of treating brain tumors according to claim 8, wherein said nanoparticle complex comprises metal nanoparticles surface-modified with lactoferrin and glutathione, and said lactoferrin is surface-modified with a biocompatible polymer.

### Claim 11 (depends on 10)

The method of treating brain tumors according to claim 10, wherein said biocompatible polymer is selected from the group consisting of polyethylene glycol, polycaprolactone, polylactic acid, polyglycolic acid, polylactate-co-glycolic acid, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(L-lactide-co-caprolactone), and poly(L-lactide-co-D-lactide).

### Claim 12 (depends on 8)

The method of treating brain tumors according to claim 8, wherein said nanoparticle complex is orally administered.

### Claim 13 (depends on 1)

A photothermal or photodynamic treatment method comprising steps of administering the nanoparticle complex of claim 1 to a subject; and irradiating with a light beam a treatment target site of the subject administered with the nanoparticle complex.

### Claim 14 (depends on 13)

The photothermal or photodynamic treatment method according to claim 13, wherein said metal nanoparticles are selected from the group consisting of gold nanoparticles, iron oxide nanoparticles, and silver nanoparticles.

### Claim 15 (depends on 13)

The photothermal or photodynamic treatment method according to claim 13, wherein said nanoparticle complex comprises metal nanoparticles surface-modified with lactoferrin and glutathione, and said lactoferrin is surface-modified with a biocompatible polymer.

### Claim 16 (depends on 15)

The photothermal or photodynamic treatment method according to claim 15, wherein said biocompatible polymer is selected from the group consisting of polyethylene glycol, polycaprolactone, polylactic acid, polyglycolic acid, polylactate-co-glycolic acid, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(L-lactide-co-caprolactone), and poly(L-lactide-co-D-lactide).

### Claim 17 (depends on 13)

The photothermal or photodynamic treatment method according to claim 13, wherein said treatment target site is brain tissues.

### Claim 18 (depends on 13)

The photothermal or photodynamic treatment method according to claim 13, wherein said nanoparticle complex is orally administered.
